Resources

HyperRAB is a higher concentration HRIG product (300 IU/mL), resulting in a lower volume per dose administered (compared to products concentrated at 150 IU/mL). For patients, this may mean fewer injections.¹

HyperRAB (300 IU/mL) is a higher concentration product. Therefore, HCPs are not only able to administer more rabies antibodies directly into the wound site, but also administer a lower volume to complete the dose for each patient.¹

HyperRAB remains stable and safe to use for 3 years when kept at a temperature of 2 to 8°C (36 to 46°F), which helps to reduce the risk of unused and expired inventory. Additionally, HyperRAB can be safely stored at room temperature (not to exceed 25°C [77°F]) for up to 6 months at any time prior to the expiration date, after which the product must be used or discarded. Do not return to refrigeration. Do not freeze HyperRAB.¹

HyperRAB is not required to be diluted for use, however, under certain circumstances when the total dose volume is insufficient to infiltrate the wound completely, HyperRAB may be diluted with an equal volume of dextrose 5% in water (D5W).¹

The Centers for Disease Control and Prevention (CDC) recommends infiltrating the wound site with as much of the total dose as possible. Bat exposures can result in either very small bites that do not require a large volume of rabies immune globulin infiltration at the wound site(s), or there may be no bite site evident or visible. If not anatomically feasible, the total dose may be administered intramuscularly.^2-5

Per the labeled indication, the rabies vaccine and HyperRAB should be administered to all individuals exposed to rabies, with the exception of those who have been previously immunized with the rabies vaccine. Although the safety and efficacy of HyperRAB in the pediatric population have not been established, the dosing regimen provided in the full Prescribing Information applies to all individuals, including children. Please contact Grifols Medical Information at 1-800-520-2807 for more information.¹

HyperRAB (300 IU/mL) is manufactured using a caprylate/chromatography purification process, which significantly reduces procoagulant activity and product impurities such as immunoglobulin G (IgG) aggregates.⁶

Learn how HRIG is manufactured

Administration of HyperRAB resulted in detectable titers of neutralizing antibodies to the rabies virus that persisted throughout the 21-day study period. Caprylate/chromatography-purified HyperRAB produced a rapid increase in rabies neutralizing antibodies within 24 hours, peaked on day 4, and was maintained through day 21. These results support the conclusion that HyperRAB administration provides reproducible passive transfer of neutralizing antibodies. The single 20 IU/kg intramuscular dose of HyperRAB was safe and well tolerated. HyperRAB should provide adequate passive adjunctive treatment when combined with vaccination in accordance with guidelines for rabies postexposure prophylaxis.^1,7

HyperRAB is available through all major specialty plasma distributors. In most instances, you should be able to gain access to HyperRAB through your existing distributor.

HyperRAB is not available on consignment through Grifols. Some specialty plasma distributors offer HyperRAB on their consignment programs. Check with your distributor for terms and conditions.

HyperRAB contains no preservatives and is not made with natural rubber latex.¹

HyperRAB should be billed using 2 units of HCPCS/CPT 90375 (150 IU) for each 1 mL (300 IU) of HyperRAB. Appropriate ICD-10 codes may be reviewed at www.HyperRAB.com.